类他类药物,高密度脂蛋白胆固醇,以及冠状动脉样硬化的回归
Stephen J Nicholls1, E Murat Tuzcu, Ilke Sipahi
1Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA. nichols1@ccf.org
JAMA
|February 8, 2007
概括
立方体治疗显著降低低密度脂蛋白胆固醇 (LDL-C) 和增加高密度脂蛋白胆固醇 (HDL-C),导致冠状动脉样硬化回归. 这些脂质变化,特别是显著的LDL-C降低和HDL-C增加,是他类药物益处的关键.
科学领域:
- 心脏病学 心脏病学
- 脂质学 脂质学是指脂质学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 已经证明,他类药物可以降低低密度脂蛋白胆固醇 (LDL-C) 和减缓冠状动脉样硬化进展.
- 高密度脂蛋白胆固醇 (HDL-C) 中因他类药物引起的变化对疾病进展的影响尚不清楚.
研究的目的:
- 检查LDL-C和HDL-C水平的变化与动脉瘤负担之间的相关性.
- 为了确定在他类药物治疗期间动脉瘤回归的预测因素.
主要方法:
- 对4项前性随机试验的后期分析,涉及1455名血管学冠状动脉疾病患者.
- 连续的血管内超声学被用来评估在18-24个月的他类药物治疗中动脉瘤体积的变化.
- 核心实验室分析确保了超声波数据解释的一致性.
主要成果:
- 达丁治疗降低了LDL-C的23.5%,并增加了HDL-C的7.5%. LDL-C与HDL-C的比率下降了26.7%.
- 动脉瘤体积显示平均减少2.4mm3,在百分比动脉瘤体积中增加了0.5%.
- 多变量分析确定了平均LDL-C水平和HDL-C的增加作为动脉瘤回归的独立预测因素. 当LDL-C低于87.5 mg/dL和HDL-C增加了>7.5%时,观察到显著的回归.
结论:
- 立方体治疗促进冠状动脉样硬化回归,特别是当LDL-C显著降低,HDL-C增加时.
- 这些发现表明,LDL-C的降低和HDL-C的增加都有助于他的心血管益处.
- 需要进一步的研究来确定这种回归是否转化为改善临床结果和减少心血管事件.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...